April 2024 • PharmaTimes Magazine • 4-5

Contents

Features

Revolutionising pharma trials – AI and data’s growing influence

The growth of biomarkers and assays in lung cancer drug clinical trials

The challenges of sustaining digital products across pharma

Scope 3 emissions – a strategic imperative for pharma companies

Transforming market access through a range of patient perspectives

Analysis

Could lessons from NHS waiting lists help boost life sciences?

Community pharmacy is finally getting new clinically based services

A much-anticipated EPA 2024 in Amsterdam – How was it for you?

Rare Disease Day – pushing for progress in clinical research

Transformative AI trends and the frantic race to stay relevant

SmartPeople

28.
Tools for life
Why do we urgently need a government men’s health ambassador

3.
Digital dynamism
Leveraging integration frameworks to realise big data’s potential

36.
Your moves
Where you're going and what you're doing when you get there

Logo

PharmaTimes

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis.

PharmaTimes print and digital magazine has a distributed circulation of 19,000, reaching right across the industry into every company and every function, bridging the gap between Pharma and the NHS.

editorial@pharmatimes.com
https://pharmatimes.com/
Privacy Policy
Terms of Service

Categories

Explore our inspiring content by topic

PharmaTimes
News
Features
Analysis
SmartPeople

Social Footprints

Follow us on our Social Media Channels

X
linkedin